Stocks to watch on Wednesday:Ambarella (AMBA) - watch out for computer vision chip hype, but not yet. Revenues are still far away on the CV1 so only load up on dips. Fitbit (FIT) - all signs point to a solid holiday season for the fitness tracking company that recently moved into smartwatches. The market doesn't expect much out of Fitbit trading at only 1x sales. Buy below $7. Snap (SNAP) - the Barclays $18 target is absurd. Snap is already worth $18 billion on the 10% jump to $15. Nothing justifies the current valuation. More research: Snap: Exclusive Engagement Isn't Enough Allergan (AGN) - the dip on Revance Therapeutics (RVNC) positive Phase 3 results for RT002 could threaten Botox market dominance. Allergen dipped even further on this news after a brutal year already, but after further review Revance doesn't plan to market this product until 2020, if approved by the FDA. The stock is starting to hit a buy zone below $165. Click on the Sign in/Sign up button in the top right corner to join for free to comment on your stock moves for tomorrow. Click on the Follow button to get daily blog posts from Out Fox The $treet. Disclosure: No position